Bendamustine Hydrochloride Powder For Concentrate For Solution For Infusion
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Bendamustine Hydrochloride 2.5mg/ml Powder for Concentrate for Solution for Infusion
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml of the concentrate contains 2.5 mg bendamustine hydrochloride when reconstituted according to section 6.6.
One vial contains 25 mg bendamustine hydrochloride.
One vial contains 100 mg bendamustine hydrochloride.
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion White to off-white lyophilisate powder
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.
Indolent non-Hodgkin's lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.
Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.
4.2 Posology and method of administration
Administration precautions
For intravenous infusion over 30-60 minutes (see section 6.6).
Infusion must be administered under the supervision of a physician qualified and experienced in the use of chemotherapeutic agents.
Poor bone marrow function is related to increased chemotherapy-induced haematological toxicity. Treatment should not be started if leukocyte and/or platelet values have dropped to < 3,000 /^l or < 75,000 /^l, respectively (see section 4.3).
Posology
Monotherapy for chronic lymphocytic leukaemia
100 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 4 weeks.
Monotherapy_for indolent non-Hodgkin's lymphomas refractory to rituximab
120 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2; every 3 weeks.
Multiple myeloma
120-150 mg/m2 body surface area bendamustine hydrochloride on days 1 and 2,
60 mg/m2 body surface area prednisone i.v. or per os on days 1 to 4; every 4 weeks.
Treatment should be terminated or delayed if leukocyte and/or platelet values have dropped to < 3,000 /^l or < 75,000 /^l, respectively. Treatment can be continued after leukocyte values have increased to> 4,000 /^l and platelet values to > 100,000 /^l.
The leukocyte and platelet Nadir is reached after 14-20 days with regeneration after 3-5 weeks. During therapy free intervals strict monitoring of the blood count is recommended (see section 4.4).
In case of non-haematological toxicity dose reductions have to be based on the worst CTC grades in the preceding cycle. A 50% dose reduction is recommended in case of CTC grade 3 toxicity. An interruption of treatment is recommended in case of CTC grade 4 toxicity.
If a patient requires a dose modification the individually calculated reduced dose must be given on day 1 and 2 of the respective treatment cycle.
Special populations
Hepatic impairment
On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with mild hepatic impairment (serum bilirubin < 1.2 mg/dl). A 30% dose reduction is recommended in patients with moderate hepatic impairment (serum bilirubin 1.2-3.0 mg/dl).
No data is available in patients with severe hepatic impairment (serum bilirubin values of > 3.0 mg/dl) (see section 4.3).
Renal impairment
On the basis of pharmacokinetic data, no dose adjustment is necessary in patients with a creatinine clearance of > 10 ml/min. Experience in patients with severe renal impairment is limited.
Paediatric population
There is no experience in children and adolescents with Bendamustine Powder. Elderly patients
There is no evidence that dose adjustments are necessary in elderly patients (see section 5.2).
Method of administration
The powder for concentrate for solution for infusion has to be reconstituted with water for injection, diluted with sodium chloride 9 mg/ml (0.9%) solution for injection and then administered by intravenous infusion.
For instructions on reconstitution, dilution and administration of the medicinal product before administration, see section 6.6.
4.3 Contraindications
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- During breast feeding
- Severe hepatic impairment (serum bilirubin > 3.0 mg/dl)
- Jaundice
- Severe bone marrow suppression and severe blood count alterations (leukocyte and/or platelet values dropped to < 3,000 /pl or < 75,000 /pl, respectively)
- Major surgery less than 30 days before start of treatment
- Infections, especially involving leukocytopenia
- Yellow fever vaccination
4.4 Special warnings and precautions for use
Myelosuppression
Patients treated with bendamustine hydrochloride may experience myelosuppression. In the event of treatment-related myelosuppression, leukocytes, platelets, haemoglobin, and neutrophils must be monitored at least weekly. Prior to the initiation of the next cycle of therapy, the following parameters are recommended: Leukocyte and/or platelet values> 4,000 /pl or> 100,000 /pl, respectively.
Infections
Infection, including pneumonia and sepsis, has been reported. In rare cases, infection has been associated with hospitalization, septic shock and death. Patients with neutropenia and/or lymphopenia following treatment with bendamustine hydrochloride are more susceptible to infections. Patients with myelosuppression following bendamustine hydrochloride treatment should be advised to contact a
physician if they have symptoms or signs of infection, including fever or respiratory symptoms.
Skin reactions
A number of skin reactions have been reported. These events have included rash, toxic skin reactions and bullous exanthema. Some events occurred when bendamustine hydrochloride was given in combination with other anticancer agents, so the precise relationship is uncertain. Where skin reactions occur, they may be progressive and increase in severity with further treatment. If skin reactions are progressive, Bendamustine Powder should be withheld or discontinued. For severe skin reactions where a relationship to bendamustine hydrochloride is suspected, treatment should be discontinued.
Patients with cardiac disorders
During treatment with bendamustine hydrochloride the concentration of potassium in the blood must be closely monitored and potassium supplement must be given when K+ < 3.5 mEq/l, and ECG measurement must be performed.
Nausea, vomiting
An antiemetic may be given for the symptomatic treatment of nausea and vomiting. Tumour lysis syndrome
Tumour lysis syndrome associated with bendamustine hydrochloride treatment has been reported in patients in clinical trials. The onset tends to be within 48 hours of the first dose of bendamustine hydrochloride and, without intervention, may lead to acute renal failure and death. Preventive measures include adequate volume status and close monitoring of blood chemistry, particularly potassium and uric acid levels. The use of allopurinol during the first one to two weeks of bendamustine hydrochloride therapy can be considered but not necessarily as standard. However, there have been a few cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis reported when bendamustine and allopurinol were administered concomitantly.
Anaphylaxis
Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials. Symptoms are generally mild and include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred. Patients must be asked about symptoms suggestive of infusion reactions after their first cycle of therapy. Measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids must be considered in subsequent cycles in patients who have previously experienced infusion reactions.
Patients who experienced Grade 3 or worse allergic-type reactions were typically not re-challenged.
Contraception
Bendamustine hydrochloride is teratogenic and mutagenic.
Women should not become pregnant during treatment. Male patients should not father a child during and up to 6 months after treatment. They should seek advice about sperm conservation prior to treatment with bendamustine hydrochloride because of possible irreversible infertility.
Extravasation
An extravasal injection should be stopped immediately. The needle should be removed after a short aspiration. Thereafter the affected area of tissue should be
cooled. The arm should be elevated. Additional treatments like the use of corticosteroids are not of clear benefit.
4.5 Interaction with other medicinal products and other forms of interaction
No in-vivo interaction studies have been performed.
When bendamustine hydrochloride is combined with myelosuppressive agents, the effect of bendamustine hydrochloride and/or the co-administered medicinal products on the bone marrow may be potentiated. Any treatment reducing the patient's performance status or impairing bone marrow function can increase the toxicity of bendamustine hydrochloride.
Combination of bendamustine hydrochloride with ciclosporin or tacrolimus may result in excessive immunosuppression with risk of lymphoproliferation.
Cytostatics can reduce antibody formation following live-virus vaccination and increase the risk of infection which may lead to fatal outcome. This risk is increased in subjects who are already immunosuppressed by their underlying disease.
Bendamustine metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme (see section 5.2). Therefore, the potential for interaction with CYP1A2 inhibitors such as fluvoxamine, ciprofloxacin, acyclovir and cimetidine exists.
4.6 Fertility, pregnancy and lactation
Pregnancy
There are insufficient data from the use of bendamustine hydrochloride in pregnant women. In nonclinical studies bendamustine hydrochloride was embryo-/fetolethal, teratogenic and genotoxic (see section 5.3). During pregnancy Bendamustine Powder should not be used unless clearly necessary. The mother should be informed about the risk to the foetus. If treatment with bendamustine hydrochloride is absolutely necessary during pregnancy or if pregnancy occurs during treatment, the patient should be informed about the risks for the unborn child and be monitored carefully. The possibility of genetic counselling should be considered.
Breast-feeding
It is not known whether bendamustine passes into breast milk, therefore, Bendamustine Powder is contraindicated during breast feeding (see section 4.3). Breast feeding must be discontinued during treatment with Bendamustine Powder.
Fertility
Women of childbearing potential must use effective methods of contraception both before and during Bendamustine Powder therapy.
Men being treated with Bendamustine Powder are advised not to father a child during and for up to 6 months following cessation of treatment. Advice on conservation of sperm should be sought prior to treatment because of the possibility of irreversible infertility due to therapy with Bendamustine Powder.
Effects on ability to drive and use machines
4.7
No studies on the effects on the ability to drive and use machines have been performed. However, ataxia, peripheral neuropathy and somnolence have been reported during treatment with bendamustine hydrochloride (see section 4.8). Patients should be instructed that if they experience these symptoms they should avoid potentially hazardous tasks such as driving and using machines.
4.8 Undesirable effects
Summary of safety profile
The most common adverse reactions with bendamustine hydrochloride are haematological adverse reactions (leukopenia, thrombopenia), dermatologic toxicities (allergic reactions), constitutional symptoms (fever), gastrointestinal symptoms (nausea, vomiting).
Tabulated list of adverse reactions
The table below reflects the data obtained with bendamustine hydrochloride in clinical trials.
Frequency categories are defined using the following convention: very common (>1/10), common (>1/100 to <1/10), uncommon (>1/1,000 to <1/100), rare (>1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).
|
MedDRA system organ class |
Frequency |
Adverse reaction |
|
Infections and infestations |
Very common |
Infection NOS* |
|
Rare |
Sepsis | |
|
Very rare |
Pneumonia primary atypical | |
|
Neoplasm benign, malignant and unspecified (including cysts and polyps) |
Common |
Tumour lysis syndrome |
|
Blood and lymphatic system |
Very common |
Leukopenia NOS*, thrombocytopenia |
|
disorders |
Common |
Haemorrhage, anaemia, neutropenia |
|
Very rare |
Haemolysis | |
|
Immune system disorders |
Common |
Hypersensitivity NOS* |
|
Rare |
Anaphylactic reaction, anaphylactoid reaction | |
|
Very rare |
Anaphylactic shock | |
|
Nervous system disorders |
Common |
Insomnia |
|
Rare |
Somnolence, aphonia | |
|
Very rare |
Dysgeusia, paraesthesia, peripheral sensory neuropathy, anticholinergic syndrome, neurological disorders, ataxia, encephalitis | |
|
Cardiac disorders |
Common |
Cardiac dysfunction, such as palpitations, angina pectoris, arrhythmia |
|
Uncommon |
Pericardial effusion | |
|
Very rare |
Tachycardia, myocardial infarction, cardiac failure |
|
Vascular disorders |
Common |
Hypotension, hypertension |
|
Rare |
Acute circulatory failure | |
|
Very rare |
Phlebitis | |
|
Respiratory, thoracic and mediastinal disorders |
Common |
Pulmonary dysfunction |
|
Very rare |
Pulmonary fibrosis | |
|
Gastrointestinal disorders |
Very common |
Nausea, vomiting |
|
Common |
Diarrhoea, constipation, stomatitis | |
|
Very rare |
Haemorrhagic oesophagitis, gastrointestinal haemorrhage | |
|
Hepatobiliary disorders |
Not known |
Hepatic failure |
|
Skin and subcutaneous tissue disorders |
Common |
Alopecia, skin disorders NOS* |
|
Rare |
Erythema, dermatitis, pruritus, macular-papular rash, hyperhidrosis | |
|
Reproductive system and breast disorders |
Common |
Amenorrhea |
|
Very rare |
Infertility | |
|
General disorders and administration site conditions |
Very common |
Mucosal inflammation, fatigue, pyrexia |
|
Common |
Pain, chills, dehydration, anorexia | |
|
Very rare |
Multi organ failure | |
|
Investigations |
Very common |
Haemoglobin decrease, creatinine increase, urea increase |
|
Common |
AST increase, ALT increase, alkaline phosphatase increase, bilirubin increase, hypokalaemia |
NOS = Not otherwise specified Description of selected adverse reaction
A small number of cases of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis have been reported in patients using bendamustine in combination with allopurinol or in combination with allopurinol and rituximab.
The CD4/CD8 ratio may be reduced. A reduction of the lymphocyte count was seen. In immuno-suppressed patients, the risk of infection (e.g. with herpes zoster) may be increased.
There have been isolated reports of necrosis after accidental extra-vascular administration and toxic epidermal necrolysis, tumour lysis syndrome and anaphylaxis.
There are reports of secondary tumours, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukaemia and bronchial carcinoma. The association with bendamustine therapy has not been determined.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard
4.9 Overdose
After application of a 30 min infusion of bendamustine hydrochloride once every 3 weeks the maximum tolerated dose (MTD) was 280 mg/m2. Cardiac events of CTC grade 2 which were compatible with ischaemic ECG changes occurred which were regarded as dose limiting.
In a subsequent study with a 30 min infusion of bendamustine hydrochloride at day 1 and 2 every 3 weeks the MTD was found to be 180 mg/m2. The dose limiting toxicity was grade 4 thrombocytopenia. Cardiac toxicity was not dose limiting with this schedule.
Counter measures
There is no specific antidote. Bone marrow transplantation and transfusions (platelets, concentrated erythrocytes) may be made or haematological growth factors may be given as effective countermeasures to control haematological side effects.
Bendamustine hydrochloride and its metabolites are dialyzable to a small extent.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, ATC code: L01AA09
Bendamustine hydrochloride is an alkylating antitumour agent with unique activity. The antineoplastic and cytocidal effect of bendamustine hydrochloride is based essentially on a cross-linking of DNA single and double strands by alkylation. As a result, DNA matrix functions and DNA synthesis and repair are impaired. The antitumour effect of bendamustine hydrochloride has been demonstrated by several in vitro studies in different human tumour cell lines (breast cancer, non-small cell and small cell lung cancer, ovarian carcinoma and different leukaemia) and in vivo in different experimental tumour models with tumours of mouse, rat and human origin (melanoma, breast cancer, sarcoma, lymphoma, leukaemia and small cell lung cancer).
Bendamustine hydrochloride showed an activity profile in human tumour cell lines different to that of other alkylating agents. The active substance revealed no or very low cross-resistance in human tumour cell lines with different resistance mechanisms at least in part due to a comparatively persistent DNA interaction. Additionally, it was shown in clinical studies that there is no complete cross-resistance of bendamustine with anthracyclines, alkylating agents or rituximab. However, the number of assessed patients is small.
Chronic lymphocytic leukaemia
The indication for use in chronic lymphocytic leukaemia is supported by a single open label study comparing bendamustine with chlorambucil. In the prospective, multi-centre, randomised study, 319 previously untreated patients with chronic lymphocytic leukaemia stage Binet B or C requiring therapy were included. The first line therapy with bendamustine hydrochloride 100 mg/m2 i.v. on days 1 and 2 (BEN) was compared to treatment with chlorambucil 0.8 mg/kg days 1 and 15 (CLB) for 6 cycles in both arms. Patients received allopurinol in order to prevent tumour lysis syndrome.
Patients with BEN had a significantly longer median progression free survival than patients with CLB treatment (21.5 versus 8.3 months, p < 0.0001 in the latest follow-up). Overall survival was not statistically significantly different (median not reached). The median duration of remission was 19 months with BEN and 6 months with CLB treatment (p < 0.0001). The safety evaluation in both treatment arms did not reveal any unexpected undesirable effects in nature and frequency. The dose of BEN was reduced in 34% of the patients. Treatment with BEN was discontinued in 3.9% of patients due to allergic reactions.
Indolent non-Hodgkin's lymphomas
The indication for indolent non-Hodgkin's lymphomas relied on two uncontrolled phase II trials.
In the pivotal prospective, multi-centre, open study 100 patients with indolent B-cell non-Hodgkins lymphomas refractory to rituximab mono- or combination therapy were treated with BEN single agent. Patients had received a median of 3 previous chemotherapy or biological therapy courses. The median number of previous rituximab-containing courses was 2. The patients had had no response or there had been progression within 6 months after rituximab treatment. The dose of BEN was 120 mg/m2 i.v. on days 1 and 2 planned for at least 6 cycles. Duration of treatment depended on response (6 cycles planned). The overall response rate was 75% including 17% complete (CR and CRu) and 58% partial response as assessed by independent review committee. The median duration of remission was 40 weeks.
BEN was generally well tolerated when given in this dose and schedule.
The indication is further supported by another prospective, multi-centre, open study including 77 patients. The patient population was more heterogeneous including: indolent or transformed B-cell non-Hodgkin's lymphomas refractory to rituximab mono- or combination therapy. The patients had no response or there had been progression within 6 months or had had an untoward reaction to prior rituximab treatment. Patients had received a median of 3 previous chemotherapy or biological therapy courses. The median number of previous rituximab-containing courses had been 2. The overall response rate was 76% with a median duration of response of 5 months (29 [95% CI 22.1, 43.1] weeks).
Multiple myeloma
In a prospective, multi-centre, randomised, open study 131 patients with advanced multiple myeloma (Durie-Salmon stage II with progression or stage III) were included. The first line therapy with bendamustine hydrochloride in combination with prednisone (BP) was compared to treatment with melphalan and prednisone (MP). Neither transplant-eligibility nor the presence of specific co-morbidities played a role for inclusion into the trial. The dose was bendamustine hydrochloride 150 mg/m2 i.v. on days 1 and 2 or melphalan 15 mg/m2 i.v. on day 1 each in combination with prednisone. Duration of treatment depended on response and averaged 6.8 cycles in the BP and 8.7 cycles in the MP group.
Patients with BP treatment had a longer median progression free survival than patients with MP (15 [95% CI 12-21] versus 12 [95% CI 10-14] months)
(p = 0.0566). The median time to treatment failure was 14 months with BP and 9 months with MP treatment. The duration of remission was 18 months with BP and 12 months with MP treatment. The difference in overall survival was not significantly different (35 months BP versus 33 months MP). Tolerability in both treatment arms was in line with the known safety profile of the respective medicinal products with significantly more dose reductions in the BP arm.
5.2 Pharmacokinetic properties
Distribution
The elimination half-life ti/2B after 30 min i.v. infusion of 120 mg/m2 area to 12 subjects was 28.2 minutes.
Following 30 min i.v. infusion the central volume of distribution was 19.3 l. Under steady-state conditions following i.v. bolus injection the volume of distribution was 15.8-20.5 l.
More than 95% of the substance is bound to plasma proteins (primarily albumin). Metabolism
A major route of clearance of bendamustine is the hydrolysis to monohydroxy- and dihydroxy-bendamustine. Formation of N-desmethyl-bendamustine and gamma-hydroxy-bendamustine by hepatic metabolism involves cytochrome P450 (CYP) 1A2 isoenzyme. Another major route of bendamustine metabolism involves conjugation with glutathione.
In-vitro bendamustine does not inhibit CYP 1A4, CYP 2C9/10, CYP 2D6, CYP 2E1 or CYP 3A4.
Elimination
The mean total clearance after 30 min i.v. infusion of 120 mg/m2 body surface area to 12 subjects was 639.4 ml/minute. About 20% of the administered dose was recovered in urine within 24 hours. Amounts excreted in urine were in the order monohydroxy-bendamustine> bendamustine> dihydroxy-bendamustine> oxidised metabolite> N-desmethyl bendamustine. In the bile, primarily polar metabolites are eliminated.
Hepatic impairment
In patients with 30-70% tumour infestation of the liver and mild hepatic impairment (serum bilirubin < 1.2 mg/dl) the pharmacokinetic behaviour was not changed. There was no significant difference to patients with normal liver and kidney function with respect to Cmax, tmax, AUC, t1/2B , volume of distribution and clearance. AUC and total body clearance of bendamustine correlate inversely with serum bilirubin.
Renal impairment
In patients with creatinine clearance> 10 ml/min including dialysis dependent patients, no significant difference to patients with normal liver and kidney function was observed with respect to Cmax, tmax, AUC, t1/2B, volume of distribution and clearance.
Elderly subjects
Subjects up to 84 years of age were included in pharmacokinetic studies. Higher age does not influence the pharmacokinetics of bendamustine.
5.3 Preclinical safety data
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:
Histological investigations in dogs showed macroscopic visible hyperaemia of the mucosa and haemorrhagia in the gastrointestinal tract. Microscopic investigations showed extensive changes of the lymphatic tissue indicating an immunosuppression and tubular changes of kidneys and testis, as well as atrophic, necrotic changes of the prostate epithelium.
Animal studies showed that bendamustine is embryotoxic and teratogenic.
Bendamustine induces aberrations of the chromosomes and is mutagenic in vivo as well as in vitro. In long-term studies in female mice bendamustine is carcinogenic.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Mannitol
6.2 Incompatibilities
This medicinal product must not be mixed with other medicinal products
except those mentioned in section 6.6.
6.3 Shelf life
Before opening: 2 years Reconstituted concentrate
The powder should be reconstituted immediately after opening of the vial.
The reconstituted concentrate should be diluted immediately with 0.9% sodium chloride solution (see section 6.6).
Solution for infusion
After reconstitution and dilution, chemical and physical stability has been demonstrated for 3.5 hours at 25 °C/ 60% RH, in normal light conditions and 2 days at 2 °C to 8 °C, protected from light, in polyethylene bags.
From a microbiological point of view, the solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
6.4 Special precautions for storage
Unopened: This medicinal product does not require any special storage conditions.
For storage conditions after reconstitution or dilution of the medicinal product, see section 6.3.
6.5 Nature and contents of container
Type I amber glass vials of 26 ml or 60 ml with type I rubber (bromobutyl) lyo-stopper and an aluminium cap with polypropylene disk. Vials are sheathed in protective sleeve.
26 ml-vials contain 25 mg bendamustine hydrochloride and are supplied in packs of 1, 5, 10 and 20 vials.
60 ml-vials contain 100 mg bendamustine hydrochloride and are supplied in packs of 1 and 5 vials.
Not all pack sizes may be marketed.
6.6 Special precautions for disposal
When handling Bendamustine Powder, inhalation, skin contact or contact with mucous membranes should be avoided (wear gloves and protective clothes!). Contaminated body parts should be carefully rinsed with water and soap, the eyes should be rinsed with physiological saline solution. If possible it is recommended to work on special safety workbenches (laminar flow) with liquid impermeable, absorbent disposable foil. Pregnant personnel should be excluded from handling cytostatics.
The powder for concentrate for solution for infusion has to be reconstituted with water for injection, diluted with sodium chloride 9 mg/ml (0.9%) solution for injection and then administered by intravenous infusion. Aseptic technique is to be used.
1. Reconstitution
Reconstitute each vial of Bendamustine Powder containing 25 mg bendamustine hydrochloride in 10 ml water for injection by shaking;
Reconstitute each vial of Bendamustine Powder containing 100 mg bendamustine hydrochloride in 40 ml water for injection by shaking.
The reconstituted concentrate contains 2.5 mg bendamustine hydrochloride per ml and appears as a clear colourless solution.
2. Dilution
As soon as a clear solution is obtained (usually after 5-10 minutes) dilute the total recommended dose of Bendamustine Powder immediately with 0.9% NaCl solution to produce a final volume of about 500 ml.
Bendamustine Powder must be diluted with 0.9% NaCl solution and not with any other injectable solution.
3. Administration
The solution is administered by intravenous infusion over 30-60 min.
The vials are for single use only.
The medicinal product should not be used if any visible signs of deterioration or damages to the vials are detected. Following reconstitution and dilution, the product should be inspected visually for particulate matter or discolouration. The solution should only be used if the solution is clear and free from particles.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
7 MARKETING AUTHORISATION HOLDER
Actavis Group PTC ehf.
Reykjavikurvegi 76-78 220 Hafnarfjordur Iceland
8 MARKETING AUTHORISATION NUMBER(S)
PL 30306/0571
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10/12/2015
10 DATE OF REVISION OF THE TEXT
10/12/2015